 | • レポートコード：GIR201114799 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、ペプチドベース感染症治療薬の世界市場を調査対象にし、ペプチドベース感染症治療薬の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（テラプレビル、ソフォスブビル、その他）、用途別分析（病院薬局、小売薬局、オンライン薬局）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Gilead Sciences、Mitsubishi Tanabe Pharma、Johnson & Johnson (Janssen)、Vertex Pharmaceuticals、Medivir ・企業別売上、市場シェア ・ペプチドベース感染症治療薬の地域別市場分析 ・ペプチドベース感染症治療薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・ペプチドベース感染症治療薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・ペプチドベース感染症治療薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・ペプチドベース感染症治療薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・ペプチドベース感染症治療薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・ペプチドベース感染症治療薬の種類別市場規模2015-2020：テラプレビル、ソフォスブビル、その他 ・ペプチドベース感染症治療薬の用途別市場規模2015-2020：病院薬局、小売薬局、オンライン薬局 ・ペプチドベース感染症治療薬の世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論 |
Market Overview
The global Peptide Based Infection Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.1% in the forecast period of 2020 to 2025 and will expected to reach USD 28730 million by 2025, from USD 23550 million in 2019.
The Peptide Based Infection Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Peptide Based Infection Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Peptide Based Infection Therapeutics market has been segmented into:
Telaprevir
Sofosbuvir
Others
By Application, Peptide Based Infection Therapeutics has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Peptide Based Infection Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Peptide Based Infection Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Peptide Based Infection Therapeutics market.
The report offers in-depth assessment of the growth and other aspects of the Peptide Based Infection Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Peptide Based Infection Therapeutics Market Share Analysis
Peptide Based Infection Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Peptide Based Infection Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Peptide Based Infection Therapeutics sales, revenue and market share for each player covered in this report.
The major players covered in Peptide Based Infection Therapeutics are:
Gilead Sciences
Mitsubishi Tanabe Pharma
Johnson & Johnson (Janssen)
Vertex Pharmaceuticals
Medivir
Table of Contents
1 Peptide Based Infection Therapeutics Market Overview
1.1 Product Overview and Scope of Peptide Based Infection Therapeutics
1.2 Classification of Peptide Based Infection Therapeutics by Type
1.2.1 Global Peptide Based Infection Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Peptide Based Infection Therapeutics Revenue Market Share by Type in 2019
1.2.3 Telaprevir
1.2.4 Sofosbuvir
1.2.5 Others
1.3 Global Peptide Based Infection Therapeutics Market by Application
1.3.1 Overview: Global Peptide Based Infection Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Peptide Based Infection Therapeutics Market by Regions
1.4.1 Global Peptide Based Infection Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Peptide Based Infection Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Peptide Based Infection Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Peptide Based Infection Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Peptide Based Infection Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Peptide Based Infection Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Peptide Based Infection Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Gilead Sciences
2.1.1 Gilead Sciences Details
2.1.2 Gilead Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Gilead Sciences SWOT Analysis
2.1.4 Gilead Sciences Product and Services
2.1.5 Gilead Sciences Peptide Based Infection Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Mitsubishi Tanabe Pharma
2.2.1 Mitsubishi Tanabe Pharma Details
2.2.2 Mitsubishi Tanabe Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Mitsubishi Tanabe Pharma SWOT Analysis
2.2.4 Mitsubishi Tanabe Pharma Product and Services
2.2.5 Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Johnson & Johnson (Janssen)
2.3.1 Johnson & Johnson (Janssen) Details
2.3.2 Johnson & Johnson (Janssen) Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Johnson & Johnson (Janssen) SWOT Analysis
2.3.4 Johnson & Johnson (Janssen) Product and Services
2.3.5 Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Vertex Pharmaceuticals
2.4.1 Vertex Pharmaceuticals Details
2.4.2 Vertex Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Vertex Pharmaceuticals SWOT Analysis
2.4.4 Vertex Pharmaceuticals Product and Services
2.4.5 Vertex Pharmaceuticals Peptide Based Infection Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Medivir
2.5.1 Medivir Details
2.5.2 Medivir Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Medivir SWOT Analysis
2.5.4 Medivir Product and Services
2.5.5 Medivir Peptide Based Infection Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Peptide Based Infection Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Peptide Based Infection Therapeutics Players Market Share
3.2.2 Top 10 Peptide Based Infection Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Peptide Based Infection Therapeutics Revenue and Market Share by Regions
4.2 North America Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Peptide Based Infection Therapeutics Revenue by Countries
5.1 North America Peptide Based Infection Therapeutics Revenue by Countries (2015-2020)
5.2 USA Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Peptide Based Infection Therapeutics Revenue by Countries
6.1 Europe Peptide Based Infection Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Peptide Based Infection Therapeutics Revenue by Countries
7.1 Asia-Pacific Peptide Based Infection Therapeutics Revenue by Countries (2015-2020)
7.2 China Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Peptide Based Infection Therapeutics Revenue by Countries
8.1 South America Peptide Based Infection Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Peptide Based Infection Therapeutics by Countries
9.1 Middle East & Africa Peptide Based Infection Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Peptide Based Infection Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Peptide Based Infection Therapeutics Market Forecast by Type (2019-2024)
10.3 Telaprevir Revenue Growth Rate (2015-2025)
10.4 Sofosbuvir Revenue Growth Rate (2015-2025)
10.5 Others Revenue Growth Rate (2015-2025)
11 Global Peptide Based Infection Therapeutics Market Segment by Application
11.1 Global Peptide Based Infection Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Peptide Based Infection Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacies Revenue Growth (2015-2020)
11.4 Retail Pharmacies Revenue Growth (2015-2020)
11.5 Online Pharmacies Revenue Growth (2015-2020)
12 Global Peptide Based Infection Therapeutics Market Size Forecast (2021-2025)
12.1 Global Peptide Based Infection Therapeutics Market Size Forecast (2021-2025)
12.2 Global Peptide Based Infection Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Peptide Based Infection Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Peptide Based Infection Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Peptide Based Infection Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Peptide Based Infection Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Gilead Sciences Corporate Information, Location and Competitors
Table 6. Gilead Sciences Peptide Based Infection Therapeutics Major Business
Table 7. Gilead Sciences Peptide Based Infection Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Gilead Sciences SWOT Analysis
Table 9. Gilead Sciences Peptide Based Infection Therapeutics Product and Solutions
Table 10. Gilead Sciences Peptide Based Infection Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Mitsubishi Tanabe Pharma Corporate Information, Location and Competitors
Table 12. Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Major Business
Table 13. Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Mitsubishi Tanabe Pharma SWOT Analysis
Table 15. Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Product and Solutions
Table 16. Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Johnson & Johnson (Janssen) Corporate Information, Location and Competitors
Table 18. Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Major Business
Table 19. Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Johnson & Johnson (Janssen) SWOT Analysis
Table 21. Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Product and Solutions
Table 22. Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Vertex Pharmaceuticals Corporate Information, Location and Competitors
Table 24. Vertex Pharmaceuticals Peptide Based Infection Therapeutics Major Business
Table 25. Vertex Pharmaceuticals Peptide Based Infection Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Vertex Pharmaceuticals SWOT Analysis
Table 27. Vertex Pharmaceuticals Peptide Based Infection Therapeutics Product and Solutions
Table 28. Vertex Pharmaceuticals Peptide Based Infection Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Medivir Corporate Information, Location and Competitors
Table 30. Medivir Peptide Based Infection Therapeutics Major Business
Table 31. Medivir Peptide Based Infection Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Medivir SWOT Analysis
Table 33. Medivir Peptide Based Infection Therapeutics Product and Solutions
Table 34. Medivir Peptide Based Infection Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Global Peptide Based Infection Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 36. Global Peptide Based Infection Therapeutics Revenue Share by Players (2015-2020)
Table 37. Global Peptide Based Infection Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 38. Global Peptide Based Infection Therapeutics Revenue Market Share by Regions (2015-2020)
Table 39. North America Peptide Based Infection Therapeutics Revenue by Countries (2015-2020)
Table 40. North America Peptide Based Infection Therapeutics Revenue Market Share by Countries (2015-2020)
Table 41. Europe Peptide Based Infection Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 42. Asia-Pacific Peptide Based Infection Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 43. South America Peptide Based Infection Therapeutics Revenue by Countries (2015-2020)
Table 44. South America Peptide Based Infection Therapeutics Revenue Market Share by Countries (2015-2020)
Table 45. Middle East and Africa Peptide Based Infection Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 46. Middle East and Africa Peptide Based Infection Therapeutics Revenue Market Share by Countries (2015-2020)
Table 47. Global Peptide Based Infection Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 48. Global Peptide Based Infection Therapeutics Revenue Share by Type (2015-2020)
Table 49. Global Peptide Based Infection Therapeutics Revenue Forecast by Type (2021-2025)
Table 50. Global Peptide Based Infection Therapeutics Revenue by Application (2015-2020)
Table 51. Global Peptide Based Infection Therapeutics Revenue Share by Application (2015-2020)
Table 52. Global Peptide Based Infection Therapeutics Revenue Forecast by Application (2021-2025)
Table 53. Global Peptide Based Infection Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Peptide Based Infection Therapeutics Picture
Figure 2. Global Peptide Based Infection Therapeutics Revenue Market Share by Type in 2019
Figure 3. Telaprevir Picture
Figure 4. Sofosbuvir Picture
Figure 5. Others Picture
Figure 6. Peptide Based Infection Therapeutics Revenue Market Share by Application in 2019
Figure 7. Hospital Pharmacies Picture
Figure 8. Retail Pharmacies Picture
Figure 9. Online Pharmacies Picture
Figure 10. Global Peptide Based Infection Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Peptide Based Infection Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Peptide Based Infection Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Peptide Based Infection Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Peptide Based Infection Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Peptide Based Infection Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Peptide Based Infection Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Peptide Based Infection Therapeutics Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Peptide Based Infection Therapeutics Revenue Market Share in 2019
Figure 19. Global Top 10 Players Peptide Based Infection Therapeutics Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Peptide Based Infection Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Peptide Based Infection Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 23. Global Peptide Based Infection Therapeutics Revenue Market Share by Regions in 2018
Figure 24. North America Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. Europe Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. South America Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. North America Peptide Based Infection Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 30. North America Peptide Based Infection Therapeutics Revenue Market Share by Countries in 2019
Figure 31. USA Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Canada Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Europe Peptide Based Infection Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Peptide Based Infection Therapeutics Revenue Market Share by Countries in 2019
Figure 36. Germany Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. UK Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. France Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Russia Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Italy Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Peptide Based Infection Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Peptide Based Infection Therapeutics Revenue Market Share by Countries in 2019
Figure 43. China Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Japan Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Korea Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. India Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. South America Peptide Based Infection Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 49. South America Peptide Based Infection Therapeutics Revenue Market Share by Countries in 2019
Figure 50. Brazil Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Peptide Based Infection Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Peptide Based Infection Therapeutics Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. UAE Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Peptide Based Infection Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Global Peptide Based Infection Therapeutics Revenue Share by Type (2015-2020)
Figure 59. Global Peptide Based Infection Therapeutics Revenue Share by Type in 2019
Figure 60. Global Peptide Based Infection Therapeutics Market Share Forecast by Type (2021-2025)
Figure 61. Global Telaprevir Revenue Growth Rate (2015-2020)
Figure 62. Global Sofosbuvir Revenue Growth Rate (2015-2020)
Figure 63. Global Others Revenue Growth Rate (2015-2020)
Figure 64. Global Peptide Based Infection Therapeutics Revenue Share by Application (2015-2020)
Figure 65. Global Peptide Based Infection Therapeutics Revenue Share by Application in 2019
Figure 66. Global Peptide Based Infection Therapeutics Market Share Forecast by Application (2021-2025)
Figure 67. Global Hospital Pharmacies Revenue Growth Rate (2015-2020)
Figure 68. Global Retail Pharmacies Revenue Growth Rate (2015-2020)
Figure 69. Global Online Pharmacies Revenue Growth Rate (2015-2020)
Figure 70. Global Peptide Based Infection Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Peptide Based Infection Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Peptide Based Infection Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Europe Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. South America Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Peptide Based Infection Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
ペプチドベース胃腸障害治療薬の世界市場 2020年 Market Overview The global Peptide Based Gastrointestinal Disorders Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2…- ペプチドベース癌治療薬の世界市場 2020年 Market Overview The global Peptide Based Cancer Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Peptide Bas…
- ペプチドベース代謝障害治療薬の世界市場 2020年 Market Overview The global Peptide Based Metabolic Disorders Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. Th…
- ペプチドベース心血管治療薬の世界市場 2020年 Market Overview The global Peptide Based Cardiovascular Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Pep…
- マールブルクウイルス感染症の世界市場 2020年 Market Overview The global Marburgvirus Infection market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Marburgvirus Infection…